2022
Population‐level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost‐effectiveness analysis
Savinkina A, Madushani RWMA, Yazdi G, Wang J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population‐level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost‐effectiveness analysis. Addiction 2022, 117: 2450-2461. PMID: 35315162, PMCID: PMC9377514, DOI: 10.1111/add.15879.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioOpioid use disorderStandard of careUse disordersFatal overdosesDetox patientsMOUD initiationWithdrawal programInitiation of medicationHealth care sector perspectiveRisk of overdoseFatal opioid overdosesCost-effectiveness ratioCost-effectiveness analysisOpioid useHealth care spendingOutpatient careDetox programsOpioid overdosesMOUDPatientsOverdosesPopulation-level impactDisorder populationHealth effects
2021
HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
Morgan JR, Savinkina A, Pires dos Santos AG, Xue Z, Shilton S, Linas B. HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients. Advances In Therapy 2021, 38: 1690-1700. PMID: 33590445, PMCID: PMC7932931, DOI: 10.1007/s12325-021-01647-4.Peer-Reviewed Original ResearchConceptsMean HCV RNA levelHCV RNA levelsVirologic failureIU/HCV RNARNA levelsPost-treatment week 4Hepatitis C cureMean HCV RNATreatment virologic failureLevel of viremiaDirect acting antiviralsHCV viral loadTime of relapseResource-limited settingsTreatment failureViral loadElimination targetsClinical trialsWeek 4PatientsCare testOverall populationCare assaysLarger study